普通人群中高危型MASH、MetALD及酒精相关性脂肪性肝病的患病率
基于英国生物银行40,189例行肝脏MRI检查者的横断面分析,以PDFF≥5%定义脂肪性肝病,按AASLD标准分类。脂肪性肝病者中MASLD占89.0%、MetALD占7.9%、ALD占1%、高危型MASH占2.2%,后者占普通人群0.6%,代谢与炎症指标最重。
要点
- 40,189人中10,886人(27.0%)PDFF≥5%,提示脂肪性肝病。
- 脂肪性肝病者中高危型MASH占2.2%,相当于普通人群0.6%。
- 高危型MASH组肝脏脂肪均值与BMI最高,血清炎症与代谢指标升高。
核心结论
- MASLD在MRI PDFF升高的患者中常见,不同脂肪性肝病患病率存在性别与BMI差异,高危型MASH代谢与炎症特征最重。
- 本研究为监管机构批准药物治疗后符合条件的高危型MASH人群提供了新的患病率估计。
研究设计与样本
- 对英国生物银行中40,189例行肝脏MRI检查者进行横断面分析。
- 以质子密度脂肪分数(PDFF)≥5%判定肝脂肪变,按AASLD标准分为ALD、MASLD、MetALD和高危型MASH。
主要发现
- 40,189人中10,886人(27.0%)PDFF≥5%,提示脂肪性肝病。
- 脂肪性肝病者中ALD占1%、MASLD占89.0%、MetALD占7.9%、高危型MASH占2.2%。
- 高危型MASH组占普通人群0.6%,其MRI肝脏脂肪均值与BMI最高,血清生物标志物提示炎症与代谢改变增加。
- BMI≥30 kg/m2的男性MASLD患病率显著更高;非肥胖女性MASLD风险仅12%。
- MetALD在肥胖男性和女性中患病率相似,在非肥胖女性中不存在。
关键数值与推荐
- 肝脂肪变判定阈值:PDFF≥5%。
- 分类标准:AASLD标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of at-risk metabolic dysfunction-associated steatohepatitis (at-risk MASH) has not been systematically assessed. AIM: To delineate the prevalence of at-risk MASH in a large population-based cohort. METHODS: We conducted a cross-sectional analysis of 40,189 patients in the UK Biobank who underwent liver MRI. Hepatic steatosis was determined by proton density fat fraction (PDFF) ≥5%. Based on AASLD criteria, participants were classified as alcohol-associated steatotic liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), combined metabolic alcoholic liver disease (MetALD) and at-risk MASH. RESULTS: Among 40,189 patients, 10,886 (27.0%) had a PDFF ≥5%, indicating SLD. Among patients with SLD, 1% had ALD, 89.0% had MASLD, 7.9% had MetALD and 2.2% had at-risk MASH. The at-risk MASH group, which included 0.6% of the general population, had the highest mean liver fat on MRI and the highest BMI. Serum biomarkers highlighted increased inflammation and metabolic changes in at-risk MASH. The prevalence of MASLD was significantly higher among men with a BMI ≥30 kg/m2. Non-obese women showed only a 12% risk of MASLD. Conversely, MetALD had similar prevalence in obese men and women and was absent in non-obese women. CONCLUSIONS: MASLD is prevalent among patients with elevated PDFF on MRI. There are different sex- and BMI-specific prevalence of different steatotic liver disorders. At-risk MASH demonstrates the most severe metabolic and inflammatory profiles. This study provides novel estimates for the at-risk MASH population that will be eligible for treatment with pharmacologic therapy when approved by regulatory authorities.
引用
- Schneider CV, Schneider KM, Raptis A, et al. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment Pharmacol Ther. 2024. PMID: 38500443. doi:10.1111/apt.17958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。